drug

ORKA-001

Phase 2updated 5mo ago

by $ORKA Oruka Therapeutics, Inc.

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ORKA-001

phase2An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasisrecruitingn=240
phase2Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasisactive not recruitingn=160
phase2ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasisactive not recruitingn=80
phase1ORKA-001 in Healthy Volunteerscompletedn=24

News(3)

6 immunology targets to sustain a mammoth I&I market
Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
biospace · 6d ago
Oruka surges as long-acting psoriasis drug shows early promise
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
biopharma_dive · 5mo ago
STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.
stat · 5mo ago

Data sources

ClinicalTrials.gov

last refreshed 4h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

ORKA-001

Phase 2updated 5mo ago

by $ORKA Oruka Therapeutics, Inc.

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ORKA-001

phase2An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasisrecruitingn=240
phase2Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasisactive not recruitingn=160
phase2ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasisactive not recruitingn=80
phase1ORKA-001 in Healthy Volunteerscompletedn=24

News(3)

6 immunology targets to sustain a mammoth I&I market
Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
biospace · 6d ago
Oruka surges as long-acting psoriasis drug shows early promise
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
biopharma_dive · 5mo ago
STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.
stat · 5mo ago

Data sources

ClinicalTrials.gov

last refreshed 4h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

ORKA-001

all catalysts(0)

Trials studying ORKA-001

News(3)

Report a data issue

comments(0)

ORKA-001

all catalysts(0)

Trials studying ORKA-001

News(3)

Report a data issue

comments(0)